bluebird bio (BLUE) Late-Breaker ASH Abstract Provides Proof-Of-Concept - Cowen
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- US stocks close down as oil spikes 12%, job market weakens
- U.S. nonfarm payroll employment unexpectedly falls in February
- Oracle stock falls on report of scrapped Texas data center plans
- Kuwait cuts oil output as storage fills up
- Boeing reportedly nearing 500-aircraft deal with China ahead of Trump visit
- After-hours movers: Marvell, Samsara, GAP, Cooper Cos.
- After-hours movers: Broadcom, StubHub, Cracker Barrel, Grocery Outlet, Veeva Systems and more
- After-hours movers: Moderna, CrowdStrike, Ross Stores, Box and more
- After-hours movers: MongoDB, Credo, SoFi Technologies and more
- After-hours movers: Dell, Block, CoreWeave, Autodesk, MARA and more
Wedbush Affirms bluebird bio (BLUE) at 'Outperform'; Late-Breaking ASH Data Bodes Will for bb2121
November 16, 2015 12:40 PM UTCWedbush affirms bluebird bio (Nasdaq: BLUE) with an Pit[erfpr, ratomg amd $165 price target after the company reported Phase 1 results in a late-breaking abstract from a NCI-sponsored study of anti-BCMA CAR-T cells dosed in multiple myeloma patients.
Analyst David M. Nierengarten noted, At lower doses (0.3-1 x 106 cells), 1 patient demonstrated a partial response (PR)... More
